News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
627,219 Results
Type
Article (48199)
Company Profile (218)
Press Release (578802)
Multimedia
Podcasts (109)
Webinars (14)
Section
Business (177636)
Career Advice (2598)
Deals (32717)
Drug Delivery (124)
Drug Development (79232)
Employer Resources (165)
FDA (16364)
Job Trends (13691)
News (314656)
Policy (32593)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (6)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (13)
2024 Biotech Beach Digital (6)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (3)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (5)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2433)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (83)
Alliances (44981)
ALS (94)
Alzheimer's disease (1462)
Antibody-drug conjugate (ADC) (147)
Approvals (16332)
Artificial intelligence (268)
Autoimmune disease (27)
Automation (12)
Bankruptcy (329)
Best Places to Work (10204)
BIOSECURE Act (22)
Biosimilars (118)
Biotechnology (114)
Bladder cancer (81)
Brain cancer (30)
Breast cancer (277)
Cancer (2244)
Cardiovascular disease (187)
Career advice (2165)
Career pathing (34)
CAR-T (151)
Cell therapy (437)
Cervical cancer (19)
Clinical research (64525)
Collaboration (806)
Compensation (534)
Complete response letters (29)
COVID-19 (2670)
CRISPR (42)
C-suite (234)
Cystic fibrosis (97)
Data (2115)
Decentralized trials (2)
Denatured (27)
Depression (51)
Diabetes (277)
Diagnostics (5654)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (42)
Drug discovery (121)
Drug pricing (124)
Drug shortages (32)
Duchenne muscular dystrophy (97)
Earnings (70530)
Editorial (43)
Employer branding (21)
Employer resources (147)
Events (95315)
Executive appointments (703)
FDA (17613)
Featured Employer (42)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (689)
Gene editing (104)
Generative AI (24)
Gene therapy (323)
GLP-1 (819)
Government (4064)
Grass and pollen (6)
Guidances (51)
Healthcare (16056)
Huntington's disease (25)
IgA nephropathy (31)
Immunology and inflammation (139)
Indications (29)
Infectious disease (2822)
Inflammatory bowel disease (141)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (95)
Interviews (476)
IPO (15375)
IRA (49)
Job creations (3887)
Job search strategy (1815)
Kidney cancer (11)
Labor market (35)
Layoffs (523)
Leadership (23)
Legal (7912)
Liver cancer (77)
Lung cancer (320)
Lymphoma (153)
Machine learning (7)
Management (58)
Manufacturing (321)
MASH (72)
Medical device (11592)
Medtech (11596)
Mergers & acquisitions (17881)
Metabolic disorders (758)
Multiple sclerosis (85)
NASH (23)
Neurodegenerative disease (105)
Neuropsychiatric disorders (34)
Neuroscience (2033)
NextGen: Class of 2025 (5535)
Non-profit (3442)
Northern California (2554)
Now hiring (29)
Obesity (418)
Opinion (263)
Ovarian cancer (69)
Pain (89)
Pancreatic cancer (80)
Parkinson's disease (156)
Partnered (18)
Patents (236)
Patient recruitment (105)
Peanut (46)
People (52598)
Pharmaceutical (89)
Pharmacy benefit managers (21)
Phase I (19876)
Phase II (28007)
Phase III (21860)
Pipeline (1200)
Policy (167)
Postmarket research (2627)
Preclinical (8103)
Press Release (50)
Prostate cancer (111)
Psychedelics (37)
Radiopharmaceuticals (249)
Rare diseases (408)
Real estate (5415)
Recruiting (66)
Regulatory (22827)
Reports (35)
Research institute (2236)
Resumes & cover letters (429)
Rett syndrome (4)
RNA editing (4)
RSV (47)
Schizophrenia (79)
Series A (128)
Series B (82)
Service/supplier (14)
Sickle cell disease (56)
Southern California (2186)
Special edition (18)
Spinal muscular atrophy (154)
Sponsored (33)
Startups (3350)
State (2)
Stomach cancer (16)
Supply chain (74)
Tariffs (43)
The Weekly (80)
United States (21841)
Vaccines (776)
Venture capitalists (43)
Weight loss (301)
Women's health (34)
Worklife (19)
Date
Today (205)
Last 7 days (872)
Last 30 days (2666)
Last 365 days (32028)
2025 (10433)
2024 (33924)
2023 (37974)
2022 (48616)
2021 (52387)
2020 (49762)
2019 (40585)
2018 (30990)
2017 (31325)
2016 (30100)
2015 (33767)
2014 (27445)
2013 (23121)
2012 (24762)
2011 (25359)
2010 (23333)
Location
Africa (792)
Alabama (45)
Alaska (7)
Arizona (189)
Arkansas (12)
Asia (39046)
Australia (6294)
California (5782)
Canada (1769)
China (501)
Colorado (259)
Connecticut (282)
Delaware (150)
Europe (88443)
Florida (873)
Georgia (182)
Hawaii (1)
Idaho (44)
Illinois (486)
India (27)
Indiana (268)
Iowa (11)
Japan (157)
Kansas (90)
Kentucky (21)
Louisiana (8)
Maine (64)
Maryland (877)
Massachusetts (4455)
Michigan (185)
Minnesota (348)
Mississippi (1)
Missouri (70)
Montana (18)
Nebraska (22)
Nevada (58)
New Hampshire (54)
New Jersey (1668)
New Mexico (26)
New York (1623)
North Carolina (963)
North Dakota (6)
Northern California (2554)
Ohio (170)
Oklahoma (10)
Oregon (32)
Pennsylvania (1271)
Puerto Rico (12)
Rhode Island (26)
South America (1168)
South Carolina (20)
South Dakota (1)
Southern California (2186)
Tennessee (91)
Texas (824)
Utah (155)
Virginia (142)
Washington D.C. (64)
Washington State (533)
West Virginia (3)
Wisconsin (56)
627,219 Results for "novartis pharma s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Novartis Strikes on M&A, Leading a Line of Big Pharmas With Cash to Spend
Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome sign for the biopharma ecosystem, which has been battered by macro headwinds such as tariffs and the possibility of new drug pricing pressures.
April 30, 2025
·
5 min read
·
Annalee Armstrong
Mergers & acquisitions
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
February 11, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Trump’s Tariffs Could Challenge Pharma’s Recession-Resistant Reputation
Long considered resistant to economic downturns, the pharmaceutical industry may face a greater challenge this time around as GLP-1s dominate and the population grows older.
April 8, 2025
·
5 min read
·
Annalee Armstrong
Patents
Novartis Scrambles to Squelch Copycats as Generics Gain Ground
Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto.
January 17, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Novartis Pledges $23B Boost to US Ops as Trump Intensifies Tariff Threats
Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The new facilities will include a biomedical research hub in California, two radioligand plants, and four manufacturing sites.
April 11, 2025
·
2 min read
·
Tristan Manalac
Earnings
Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
January 31, 2025
·
2 min read
·
Tristan Manalac
Earnings
Pfizer CEO Calls Trump’s Pharma National Security Concerns ‘Legitimate’
Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the pharmaceutical industry tariffs, which Trump has threatened, in part as a way to shore up U.S. national security.
April 29, 2025
·
3 min read
·
Annalee Armstrong
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
Spinal muscular atrophy
Novartis’ Intrathecal Zolgensma Effective in Older Children
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
March 19, 2025
·
6 min read
·
Heather McKenzie
Podcast
Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More
President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC director nominee; Novo Nordisk joins the triple-G race; Alnylam wins approval for Amvuttra in ATTR-CM; and Cassava Sciences ends development of simufilam in Alzheimer’s.
March 26, 2025
·
1 min read
·
Heather McKenzie
1 of 62,722
Next
